Daridorexant: First Approval

被引：0
作者：
Anthony Markham
机构：
[1] Springer Nature,
来源：
Drugs | 2022年 / 82卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Daridorexant (Quviviq™; Idorsia Pharmaceuticals Ltd.) is an orally administered dual orexin type 1 and type 2 (OX1 and OX2) receptor antagonist (DORA) being developed for the treatment of insomnia. It was selected from a pool of drug candidates on the basis of an expected effect duration of ≈ 8 h at a dose of 25 mg, with a half-life intended to minimize residual effects that might impair daytime functioning. Based on the results of two pivotal phase III trials, daridorexant was recently approved in the USA for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. This article summarizes the milestones in the development of daridorexant leading to this first approval.
引用
收藏
页码：601 / 607
页数：6
相关论文
共 50 条
[1]  
Scammell TE(2011)Orexin receptors: pharmacology and therapeutic opportunities Annu Rev Pharmacol Toxicol 51 243-266
[2]  
Winrow CJ(2018)Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study Clin Pharmacol Ther 104 1022-1029
[3]  
Muehlan C(2017)The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468 J Pharmacol Exp Ther 362 489-503
[4]  
Heuberger J(2019)Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration Eur Neuropsychopharmacol 29 847-857
[5]  
Juif PE(2021)Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease J Sleep Res 30 e13248-721
[6]  
Treiber A(2021)Impact of daridorexant, a dual orexin receptor antagonist, on cardiac repolarization following bedtime dosing: results from a thorough QT study using concentration-QT analysis Clin Drug Investig 41 711-265
[7]  
de Kanter R(2019)Metabolism of the dual orexin receptor antagonist ACT-541468, based on microtracer/ accelerator mass spectrometry Curr Drug Metab 20 254-S3
[8]  
Roch C(2021)Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, in patients with renal impairment [abstract no. 23] Eur J Clin Pharmacol 77 S2-1360
[9]  
Muehlan C(2021)Effect of liver cirrhosis on the pharmacokinetics, metabolism, and tolerability of daridorexant, a novel dual orexin receptor antagonist Clin Pharmacokinet 60 1349-819
[10]  
Brooks S(2021)Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist Br J Clin Pharmacol 88 810-104
12345